Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
134
datasets available to search
ShareScore release 0.9.0
Dataset results
134 results for “Sofosbuvir”
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
ClinicalTrials.gov study NCT02032901. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection
ClinicalTrials.gov study NCT02201953. IPD Sharing: YES. Countries: 9. Publications: 3.
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)
ClinicalTrials.gov study NCT02175966. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection
ClinicalTrials.gov study NCT01896193. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
ClinicalTrials.gov study NCT02128217. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
ClinicalTrials.gov study NCT01604850. IPD Sharing: Not stated. Countries: 4. Publications: 3.
Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection
ClinicalTrials.gov study NCT02074514. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
ClinicalTrials.gov study NCT02032888. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis
ClinicalTrials.gov study NCT02128542. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase 3 Study of Sofosbuvir and Ribavirin
ClinicalTrials.gov study NCT01497366. IPD Sharing: Not stated. Countries: 8. Publications: 2.
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
ClinicalTrials.gov study NCT01667731. IPD Sharing: Not stated. Countries: 2. Publications: 3.
Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection
ClinicalTrials.gov study NCT01909804. IPD Sharing: YES. Countries: 4. Publications: 1.
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
ClinicalTrials.gov study NCT02349048. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
ClinicalTrials.gov study NCT01542788. IPD Sharing: Not stated. Countries: 5. Publications: 2.
Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection
ClinicalTrials.gov study NCT01858766. IPD Sharing: YES. Countries: 2. Publications: 1.
Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency
ClinicalTrials.gov study NCT01958281. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients
ClinicalTrials.gov study NCT01188772. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection
ClinicalTrials.gov study NCT01826981. IPD Sharing: YES. Countries: 1. Publications: 2.
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis
ClinicalTrials.gov study NCT02114177. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Ultra-short response-guided Hepatitis C treatment with sofosbuvir and daclatasvir: the SEARCH study HCV sequence data
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.